Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients

Real-world study of efficacy and safety of PD-1 antibody monotherapy and combination therapy in pediatric lymphoma patients

Abstract Purpose Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin l...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingxia Lan, Zizheng Xiao, Yi Que, Yi Wang, Ye Hong, Juan Wang, Suying Lu, Junting Huang, Feifei Sun, Zijun Zhen, Juan Liu, Jiaqian Xu, Yanpeng Wu, Lanying Guo, M. James You, Jia Zhu, Yizhuo Zhang
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Holistic Integrative Oncology
Subjects:
Pediatric
Lymphoma
PD-1 antibodies
Toxicity
Real-world
Online Access:https://doi.org/10.1007/s44178-025-00175-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s44178-025-00175-3

Similar Items